Affinity Asset Advisors LLC raised its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 152.8% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 221,463 shares of the biopharmaceutical company’s stock after purchasing an additional 133,862 shares during the quarter. Cytokinetics accounts for about 2.6% of Affinity Asset Advisors LLC’s holdings, making […]
A number of firms have modified their ratings and price targets on shares of Cytokinetics (NASDAQ: CYTK) recently: 8/22/2023 – Cytokinetics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $59.00 price target on the stock. 8/17/2023 – Cytokinetics is now covered by analysts at StockNews.com. They set a “sell” […]
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) rose 4.7% on Friday . The stock traded as high as $36.57 and last traded at $36.57. Approximately 44,481 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 886,210 shares. The stock had previously closed at $34.94. Analysts Set […]
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average […]
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have earned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month […]